BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8205098)

  • 1. Ganciclovir and the prevention of CMV disease after allogeneic BMT: policy at the Hammersmith Hospital.
    Ward KN; Roberts IA; van Rhee F
    Bone Marrow Transplant; 1994 Feb; 13(2):230-1. PubMed ID: 8205098
    [No Abstract]   [Full Text] [Related]  

  • 2. Progress in the prevention of cytomegalovirus infection after allogeneic bone marrow transplantation.
    Devergie A; Traineau R; Esperou-Bourdeau H; Ribaud P; Socié G; Richard P; Selimi F; Hirsch I; Gluckman E
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S89-90. PubMed ID: 8177726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CMV prophylaxis in allogeneic BMT with ganciclovir and CMV immune globulin.
    Patton WN; Carter C; Bienz N; Lamb T; Boughton BJ; Franklin IM
    Bone Marrow Transplant; 1991; 7 Suppl 2():44. PubMed ID: 1652330
    [No Abstract]   [Full Text] [Related]  

  • 4. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
    Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T
    Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-emptive ganciclovir treatment can play a role in restoration of hematopoiesis after allogeneic bone marrow transplantation.
    Choi JH; Kim DW; Cho SG; Yoo JH; Jeong DC; Han CW; Shin WS; Min WS; Kim HK; Kim CC; Kim DJ
    Bone Marrow Transplant; 1997 Jan; 19(2):187-90. PubMed ID: 9116619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy.
    Avery RK; Adal KA; Longworth DL; Bolwell BJ
    Bone Marrow Transplant; 2000 Oct; 26(7):763-7. PubMed ID: 11042658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation.
    Mori T; Okamoto S; Matsuoka S; Yajima T; Wakui M; Watanabe R; Ishida A; Iwao Y; Mukai M; Hibi T; Ikeda Y
    Bone Marrow Transplant; 2000 Apr; 25(7):765-9. PubMed ID: 10745263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients.
    Ljungman P; Loré K; Aschan J; Klaesson S; Lewensohn-Fuchs I; Lönnqvist B; Ringdén O; Winiarski J; Ehrnst A
    Bone Marrow Transplant; 1996 Apr; 17(4):583-7. PubMed ID: 8722359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis.
    Nicholson VA; Whimbey E; Champlin R; Abi-Said D; Przepiorka D; Tarrand J; Chan K; Bodey GP; Goodrich JM
    Bone Marrow Transplant; 1997 Jan; 19(1):37-41. PubMed ID: 9012929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus surveillance and prevention in allogeneic bone marrow transplantation: examination of a preemptive plan of ganciclovir therapy.
    Mandanas RA; Saez RA; Selby GB; Confer DL
    Am J Hematol; 1996 Feb; 51(2):104-11. PubMed ID: 8579049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients.
    von Bueltzingsloewen A; Bordigoni P; Witz F; Bene MC; Schmitt C; Lacour B; Sommelet D
    Bone Marrow Transplant; 1993 Sep; 12(3):197-202. PubMed ID: 8241976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus infection in the bone marrow transplant recipient.
    Zaia JA; Forman SJ
    Infect Dis Clin North Am; 1995 Dec; 9(4):879-900. PubMed ID: 8747771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus disease in adult marrow transplant recipients receiving ganciclovir prophylaxis: a retrospective study.
    Maltezou H; Whimbey E; Abi-Said D; Przepiorka D; Champlin R; Goodrich J
    Bone Marrow Transplant; 1999 Sep; 24(6):665-9. PubMed ID: 10490734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prophylaxis and treatment of cytomegalovirus infection in allogeneic bone marrow transplantation].
    Guo N; Lu D; Liu D
    Zhonghua Xue Ye Xue Za Zhi; 1999 Aug; 20(8):402-4. PubMed ID: 11721418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up.
    Zaia JA; Schmidt GM; Chao NJ; Rizk NW; Nademanee AP; Niland JC; Horak DA; Lee J; Gallez-Hawkins G; Kusnierz-Glaz CR
    Biol Blood Marrow Transplant; 1995 Dec; 1(2):88-93. PubMed ID: 9118297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir.
    Ippoliti C; Morgan A; Warkentin D; van Besien K; Mehra R; Khouri I; Giralt S; Gajewski J; Champlin R; Andersson B; Przepiorka D
    Bone Marrow Transplant; 1997 Sep; 20(6):491-5. PubMed ID: 9313883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation.
    Winston DJ; Yeager AM; Chandrasekar PH; Snydman DR; Petersen FB; Territo MC;
    Clin Infect Dis; 2003 Mar; 36(6):749-58. PubMed ID: 12627359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
    Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
    Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.